Skip to main content
Equibles
COLL logo

COLL · Collegium Pharmaceutical, Inc · Metrics

Track COLL — free

Use COLL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research COLL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.50 +0.59 (+2.55%) At close · Oct 22
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$765.06M
Shares
32.56M
Volume · Oct 22 738.78K Avg daily vol (3M) 789.32K

COLL metrics

94 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$23.50
Market cap
$765.06M

Price action

20 metrics
Price change (1W)
+1.4%
Price change (30D)
+3.2%
Price change (3M)
-34.0%
Price change (6M)
-27.2%
Price change (YTD)
-49.2%
Price change (1Y)
-34.2%
Trailing year
Price change (5Y)
+11.6%
52-week high
$49.84
52-week low
$21.53
Change from 52-week high
-52.8%
Change from 52-week low
+9.2%
Annualized volatility
44.0%
Annualized volatility (3M)
51.8%
Beta
0.3
RSI (14D)
55.3
Price vs SMA 50
-1.6%
Price vs SMA 200
-30.8%
Avg volume (3M)
789,315
Relative volume
0.9
Average dollar volume
$19.80M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
32.56M

Valuation

12 metrics
P / E (TTM)
19.0
Trailing earnings · reciprocal yield 5.3%
PEG ratio
—
EV / revenue
—
EV / EBITDA
15.3×
reciprocal yield 6.5%
EV / EBIT
—
P / sales
0.9×
reciprocal yield 105.6%
P / book
2.5
reciprocal yield 40.8%
FCF yield
42.9%
TTM · current market cap
Buyback yield
—
P / FCF
2.3
reciprocal yield 42.9%
P / operating cash flow
2.3
reciprocal yield 43.1%
Earnings yield
6.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.7×
reciprocal yield 57.6%
EV / revenue historical average (5Y)
1.7×
reciprocal yield 57.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
60.0%
Operating margin
19.5%
Trailing 12 months
Net margin
5.9%
Gross profit (TTM)
$485.09M
Operating profit (TTM)
$157.44M
Net income (TTM)
$47.91M
Trailing 12 months
Diluted EPS (TTM)
$1.24
FCF margin
40.6%
Effective tax rate
38.3%

Per share

11 metrics
Revenue per diluted share (TTM)
$21.42
Gross profit per diluted share (TTM)
$12.80
Operating profit per diluted share (TTM)
$3.98
EBITDA per diluted share (TTM)
$1.13
Net income per diluted share (TTM)
$1.12
Operating cash flow per diluted share (TTM)
$8.68
Free cash flow per diluted share (TTM)
$8.64
Capital expenditures per diluted share (TTM)
$0.04
R&D per diluted share (TTM)
$0.09
Stock compensation per diluted share (TTM)
$1.21
Book value per share
$9.51

Growth

11 metrics
Revenue growth YoY
+6.3%
Year over year
Net income growth YoY
-225.6%
Revenue (TTM)
$808.21M
Trailing 12 months
EPS growth YoY
-235.3%
Shares change YoY
-16.9%
Year over year · fewer shares
Revenue CAGR (3Y)
+18.9%
Revenue CAGR (5Y)
+20.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
+17.9%
FCF CAGR (3Y)
+38.8%
FCF CAGR (5Y)
+30.0%

Quality

14 metrics
Return on equity
15.4%
Return on assets
2.2%
Debt / equity
—
Current ratio
1.0
EBITDA (TTM)
$39.65M
Free cash flow (TTM)
$328.28M
Quick ratio
0.8
Interest coverage
2.1
Net debt / EBITDA
-4.0
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$129.47M
Total assets
$2.14B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$329.92M
Capital expenditures (TTM)
$1.64M
R&D (TTM)
$3.06M
SG&A (TTM)
$327.69M
Stock compensation (TTM)
$44.93M
R&D / revenue
—
Stock compensation / revenue
5.6%

Ownership (13F)

9 metrics
13F filers
280
13F filer change QoQ
+13
Institutional ownership
120.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.9%
Holder tenure
15.6
Price vs estimated holder cost
+5.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
29.7%

Short interest

3 metrics
Short interest
16.9%
Latest settlement · 6.1 days to cover
Days to cover
6.1d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1267565 CUSIP 19459J104 13F (30d) 27 filings 27 filers Visit website Investor relations